Xeris Biopharma Holdings Inc (fra:2B30) Share Price

Company Profile

Business description
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Contact
1375 West Fulton Street
Suite 1300
ChicagoIL60607
USA
T: +1 844 445-5704
E: [email protected]
https://www.xerispharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
435

Recommended

Stocks that had been posting triple-digit returns are sliding on earnings results.

Karen Gilchrist | 12 August 2026

Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.

Nathan Zaia | 12 August 2026

The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.

Tyger Fitzpatrick | 12 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,348.40	42.10	-0.45%
CAC 40	8,674.94	40.00	-0.46%
DAX 40	26,331.07	60.35	-0.23%
Dow JONES (US)	53,770.27	21.58	-0.04%
FTSE 100	10,833.15	11.04	-0.10%
HKSE	25,347.19	92.98	-0.37%
NASDAQ	26,588.49	143.04	0.54%
Nikkei 225	68,377.88	853.82	1.26%
NZX 50 Index	13,812.83	75.17	0.55%
S&P 500	7,748.50	20.30	0.26%
S&P/ASX 200	9,151.50	41.40	-0.45%
SSE Composite Index	3,958.68	12.01	0.30%